{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "AQST", "name": "Aquestive Therapeutics, Inc.", "url": "https://frontierpicks.com/dossiers/AQST/", "json_url": "https://frontierpicks.com/dossiers/AQST.json", "status": "WATCHLIST", "current_conviction": "MEDIUM", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Aquestive Therapeutics' recovery thesis rests on an Anaphylm resubmission by 2026-09-30, following its August usability results. A filing announcement before a weekly close below $4.47 would satisfy the near-term case; missing the deadline would invalidate its timing premise.", "invalidation_trigger": "A weekly close below $4.47, the historical 200-day moving-average reference reported on 2026-09-04, breaks the recovery thesis; separately, 2026-09-30 passing without an announced Anaphylm NDA resubmission invalidates the timing premise.", "catalyst_date": "2026-09-14", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "precision-biotech-therapeutics" ], "tags": [], "sources": [], "notes": [ "Anaphylm's path runs through resubmission of a CRL'd NDA; review-clock length depends on the class the FDA assigns, which the company has not published.", "Cash was $98.5M at 2026-06-30 against $50.7M net long-term debt, and share count rose 27.37% in the trailing year — issuance is a standing feature of this story.", "Libervant holds tentative approval only; full approval is tied to a competing orphan exclusivity expiring in January 2027.", "Short interest was 20.95M shares, 18.27% of float, 7.36 days to cover on the 2026-09-04 read — moves are amplified in both directions." ], "body_markdown": "## Current Thesis\n\nAquestive Therapeutics' recovery thesis rests on resubmitting its revised Anaphylm application by 2026-09-30 before a weekly close below $4.47 breaks the recovery structure. Management reaffirmed the third-quarter New Drug Application (NDA) resubmission window on 2026-08-11. The near-term test is the filing announcement; approval remains a separate regulatory outcome. [Company update](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-second-quarter-2026-financial).\n\nAs an inference, the narrative is maturing — the market's close eased from $5.34 on 2026-09-04 to $4.78 on 2026-09-11, while the company's release archive checked on 2026-09-13 still ends with its 2026-09-01 conference announcement. That archive does not establish what management said at subsequent conferences, but it contains no newer resubmission announcement. [Company release archive](https://investors.aquestive.com/news-releases/?page=0).\n\n## Bull Case\n\n- **The revised packaging addresses usability.** Aquestive's 2026-08-10 study announcement reported median pouch-opening time of 3 seconds versus 17 seconds previously. This directly addresses a deficiency identified in the Food and Drug Administration's (FDA) 2026-01-30 Complete Response Letter; it does not establish regulatory acceptance.\n- **Existing operations generated revenue growth.** Second-quarter 2026 revenue reached $13.819 million, up 38% year over year, according to the 2026-08-11 earnings release. That balance alone does not establish funding through launch. [Quarterly results](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-second-quarter-2026-financial).\n\n## Bear Case\n\n- **Review timing remains unresolved.** The 2026-08-11 company update said an expedited review would be requested but could not be guaranteed. An FDA request for additional studies would contradict the premise that the completed work is sufficient for the regulatory repair. [Company update](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-second-quarter-2026-financial).\n- **Losses continue before regulatory resolution.** The company reported a second-quarter 2026 net loss of $22.9 million, including an $11.7 million debt-extinguishment loss, on 2026-08-11. These figures do not measure recurring cash burn. [Quarterly results](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-second-quarter-2026-financial).\n\n## Setup & Price Structure\n\nThe adjusted daily series places the 2026-09-11 close at $4.78, with a three-month price increase of 14.6% and a 14-day relative strength index (RSI) of 52.9. The comparable 2026-09-04 snapshot recorded RSI at 75.5. Momentum has cooled across those observations; they do not establish a durable base or a change in ownership.\n\nThe $4.47 research threshold comes from the 200-day moving average reported in the 2026-09-04 StockAnalysis snapshot. It remains a fixed historical reference for this thesis, not an assertion about today's moving average. An updated moving-average value is unavailable in the dated evidence.\n\nThe same 2026-09-04 StockAnalysis snapshot reported short interest at 18.27% of float and 7.36 days to cover. Those are historical positioning observations, not evidence that shorts have since covered. The company's calendar records the 2026-09-09 Cantor appearance and schedules another presentation for 2026-09-14; concentrated conference exposure does not establish broader participation. [Company events calendar](https://investors.aquestive.com/events-and-presentations).\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-30 — Guided filing window ends.** This is the quarter-end deadline implied by management's 2026-08-11 guidance, not a scheduled FDA decision. An announced resubmission by this date would satisfy the thesis's filing milestone. [Company update](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-second-quarter-2026-financial).\n\n## Elapsed catalysts\n\n- **2026-09-14 — H.C. Wainwright conference.** The company schedules its 28th Annual Global Investment Conference presentation for 9:00 a.m. Eastern Daylight Time. Any disclosed change to the filing window would alter the deadline test. [Company events calendar](https://investors.aquestive.com/events-and-presentations). *(passed 6d ago)*\n\n## What Would Change Our Mind\n\nLoss of the historical recovery reference would break the price thesis: a weekly close below $4.47, the 2026-09-04 moving-average reference, is the specified invalidation. Separately, 2026-09-30 passing without an announced Anaphylm resubmission would invalidate the timing premise.\n\nAn announced resubmission within that window, before the price condition fires, would satisfy the narrowly defined recovery case. It would leave FDA acceptance, review duration and approval unresolved; the 2026-08-11 company statement explicitly provides no guaranteed expedited timetable.\n\n## Correlation Notes\n\nThis is a single-name regulatory thesis anchored to the Anaphylm resubmission guidance dated 2026-08-11. The available evidence contains no matched peer-return series sufficient to establish a biotechnology-sector correlation. The 14.6% three-month AQST price increase measured on 2026-09-11 cannot, by itself, identify a sector contribution.", "first_seen": "2026-09-02", "last_analyzed": "2026-09-13T11:48:26+00:00", "last_synthesized": "2026-09-13", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }